drugset / Trial / NCT05503875

Immunoclassification of Psoriasis: a Strategy for Precision Medicine

NCT05503875

NaSingle-groupOpen-labelTreatment

Summary

Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.

Timeline

Start
2023-01-01
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody
Subject Guselkumab Monoclonal antibody
Subject Ixekizumab Monoclonal antibody
Subject Methotrexate Small molecule
Subject Secukinumab Monoclonal antibody

Indications